Neoadjuvant hormone therapy for radical prostate radiotherapy: Bicalutamide Monotherapy vs. Luteinizing Hormone-Releasing Hormone Agonist Monotherapy: A single-institution matched-pair analysis

Clinical Genitourinary Cancer

Volumn 10, Issue 3, 2012, Pages 190-195

  McGivern, Ursula ^a   Mitchell, Darren M ^a   McDowell, Cliona ^b   O'Hare, Jolyne ^a   Corey, Gemma ^a   O'Sullivan, Joe M ^a,c  

^a BELFAST CITY HOSPITAL   (United Kingdom)

^b ROYAL VICTORIA HOSPITAL   (United Kingdom)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Bicalutamide; LHRHa; Neoadjuvant hormone; Prostate Cancer; Radiotherapy

Indexed keywords

BICALUTAMIDE; PROSTATE SPECIFIC ANTIGEN; RECOMBINANT LUTEINIZING HORMONE;

ADULT; AGED; ARTICLE; BIOCHEMICAL FAILURE FREE SURVIVAL; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OVERALL SURVIVAL; PROSTATE CANCER; RISK ASSESSMENT; TREATMENT RESPONSE;

AGED; ANILIDES; ANTINEOPLASTIC AGENTS, HORMONAL; DISEASE-FREE SURVIVAL; GONADOTROPIN-RELEASING HORMONE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASMS, HORMONE-DEPENDENT; NITRILES; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY, CONFORMAL; RETROSPECTIVE STUDIES; TOSYL COMPOUNDS; TREATMENT OUTCOME;

EID: 84865038114     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2012.04.003     Document Type: Article

References (18)

1. M.V. Pilepich, K. Winter, M.J. John Phase III radiation oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate Int J Radiat Oncol Biol Phys 50 2001 1243 1252 (Pubitemid 32727802)
2. M. Bolla, L. Collette, L. Blank Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial Lancet 360 2002 103 106
3. J.W. Denham, A. Steigler, D.S. Lamb Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial Lancet Oncol 6 2005 841 850 (Pubitemid 41614795)
4. D.S. Lamb, J.W. Denham, D. Joseph A comparison of the prognostic value of early PSA test-based variables following external beam radiotherapy, with or without preceding androgen deprivation: analysis of data from the TROG 96.01 randomized trial Int J Radiat Oncol Biol Phys 79 2011 385 391
5. J.P. Nobes, S.E. Langley, R.W. Laing Metabolic syndrome and prostate cancer: a review Clin Oncol (R Coll Radiol) 21 2009 183 191
6. V. Murthy, A.R. Norman, M. Shahidi Recovery of serum testosterone after neoadjuvant androgen deprivation therapy and radical radiotherapy in localized prostate cancer BJU Int 97 2006 476 479
7. D.G. McLeod, P. Iversen, W.A. See Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer BJU Int 97 2006 247 254
8. K. Wellington, S.J. Keam Bicalutamide 150mg: a review of its use in the treatment of locally advanced prostate cancer Drugs 66 2006 837 850 (Pubitemid 43778730)
9. C.J. Tyrrell, A.V. Kaisary, P. Iversen A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer Eur Urol 33 1998 447 456 (Pubitemid 28251992)
10. D.M. Mitchell, J. McAleese, R.M. Park Failure to achieve a PSA level
11. A. Alexander, J. Crook, S. Jones Is biochemical response more important than duration of neoadjuvant hormone therapy before radiotherapy for clinically localized prostate cancer? An analysis of the 3- versus 8-month randomized trial Int J Radiat Oncol Biol Phys 76 2010 23 30
12. R. Malik, A.B. Jani, S.L. Liauw Prostate-specific antigen halving time while on neoadjuvant androgen deprivation therapy is associated with biochemical control in men treated with radiation therapy for localized prostate cancer Int J Radiat Oncol Biol Phys 79 2011 1022 1028
13. M. Roach, G. Hanks, H. Thames Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference Int J Radiat Oncol Biol Phys 65 2006 965 974
14. J. Cox, D. Grignon, R. Kaplan Consensus statement: guidelines for PSA following radiation therapy American Society for Therapeutic Radiology and Oncology Consensus Panel Int J Radiat Oncol Biol Phys 37 1997 1035 1041
15. G.L. Gravina, C. Festuccia, G.P. Galatioto Surgical and biologic outcomes after neoadjuvant bicalutamide treatment in prostate cancer Urology 70 2007 728 733 (Pubitemid 350030219)
16. M. Milosevic, P. Chung, C. Parker Androgen withdrawal in patients reduces prostate cancer hypoxia: implications for disease progression and radiation response Cancer Res 67 2007 6022 6025 (Pubitemid 47037480)
17. A. Henderson, S.E. Langley, R.W. Laing Is bicalutamide equivalent to goserelin for prostate volume reduction before radiation therapy? A prospective, observational study Clin Oncol (R Coll Radiol) 15 2003 316 321
18. C.N. Sternberg Apples and oranges Re: 7.4-year update of the ongoing bicalutamide early prostate cancer (EPC) trial programme BJU Int 97 2006 435 438